"Pyridazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Six-membered rings with two adjacent nitrogen atoms also called 1,2-diazine.
| Descriptor ID |
D011724
|
| MeSH Number(s) |
D03.383.710
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridazines".
Below are MeSH descriptors whose meaning is more specific than "Pyridazines".
This graph shows the total number of publications written about "Pyridazines" by people in this website by year, and whether "Pyridazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2010 | 4 | 0 | 4 |
| 2013 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyridazines" by people in Profiles.
-
The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol. 2013 Feb; 10(2):85-97.
-
A review of the safety and tolerability profile of the next-generation NNRTI etravirine. AIDS Res Hum Retroviruses. 2010 Jul; 26(7):725-33.
-
Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States. J Acquir Immune Defic Syndr. 2010 Apr; 53(5):614-8.
-
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther. 2010; 15(7):1045-52.
-
Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance. Antivir Ther. 2010; 15(6):803-16.
-
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007 Jul 07; 370(9581):39-48.